Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Etanercept decreases synovial expression of tumour necrosis factor-α and lymphotoxin-α in rheumatoid arthritis

(2013) P Neregård et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial

(2012) Brinda Emu et al.   ARTHRITIS RESEARCH & THERAPY

The time has come to limit the placebo period in rheumatoid arthritis trials to 3 months: a systematic comparison of 3- and 6-month response rates in trials of biological agents

(2009) M Boers   ANNALS OF THE RHEUMATIC DISEASES

A new design for registration trials in rheumatoid arthritis allowing secondary head-to-head comparisons with standard of care treatment including biologicals

(2009) M. Boers   ANNALS OF THE RHEUMATIC DISEASES

Inhibition of p38: Has the fat lady sung?

(2009) Mark C. Genovese   ARTHRITIS AND RHEUMATISM

Targeted depletion of lymphotoxin-α–expressing TH1 and TH17 cells inhibits autoimmune disease

(2009) Eugene Y Chiang et al.   NATURE MEDICINE

Ectopic Lymphoid Structures Support Ongoing Production of Class-Switched Autoantibodies in Rheumatoid Synovium

(2009) Frances Humby et al.   PLOS MEDICINE

Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor α, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor

(2008) Inmaculada Rioja et al.   ARTHRITIS AND RHEUMATISM

Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis

(2008) Karin Laas et al.   CLINICAL RHEUMATOLOGY

Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease

(2008) Jeffrey L. Browning   IMMUNOLOGICAL REVIEWS

High levels of Lymphotoxin-Beta (LT-Beta) gene expression in rheumatoid arthritis synovium: clinical and cytokine correlations

(2008) Killian P. O’Rourke et al.   RHEUMATOLOGY INTERNATIONAL

Tumor necrosis factor antagonist mechanisms of action: A comprehensive review

(2007) Daniel Tracey et al.   PHARMACOLOGY & THERAPEUTICS